鸟苷酸环化酶刺激剂联合RAS阻滞剂开启心力衰竭治疗新途径

A new approach to treatment of heart failure started by guanylate cyclase stimulator combined with RAS inhibitors

心力衰竭时,细胞内NO-sGC-cGMP信号通路被削弱,肾素-血管紧张素系统(RAS)异常激活参与调控cGMP/PKG信号,损害心脏功能。可溶性鸟苷酸环化酶(sGC)刺激剂是一种作用于细胞内NO-sGC-cGMP信号通路的新型药物。临床试验与动物实验均证明,在RAS阻滞剂基础上加用sGC刺激剂治疗心力衰竭,可以有效改善心脏和肾脏功能,为心力衰竭治疗提供了一条新途径。

During the progression of heart failure, the intracellular NO-sGC-cGMP pathway is suppressed, while the renin-angiotensin system(RAS) is abnormally activated and involved in the regulation of cGMP/PKG signal transduction, impairing cardiac function. Soluble guanylate cyclase(sGC) stimulant is currently a novel drug targeting the NO-sGC-cGMP signaling pathway. Clinical trials and animal experiments have proved that the treatment of heart failure with sGC stimulant, based on the use of RAS inhibitors, can effectively improve cardiac and renal function, which then provides a new way to manage this syndrome.